A major component in the hepatic synthesis of very low-density lipoprotein (VLDL) and hence LDL, is the transcription and translation of apolipoprotein B-100
(apo B100), the carrier protein of LDL.
No reports describing the use of mipomersen (Kynamro), an oligonucleotide inhibitor of apolipoprotein B-100
synthesis, in human pregnancy have been located.
Total cholesterol, HDL-c, TG, Apolipoprotein A-1 (Apo A-1), Apolipoprotein B-100
(Apo B-100) and glucose were measured in serum by standardized enzymatic automated methods in a PENTRA-400 autoanalyzer (ABX-Horiba Diagnostics, Montpellier, France).
The complete cDNA and amino acid sequence of human apolipoprotein B-100
The Kynamro injection is an oligonucleotide inhibitor of apolipoprotein B-100
synthesis and has been approved in the US for use in patients with homozygous familial hypercholesterolemia, a genetic disease characterised by extreme cholesterol levels.
Kynamro is an oligonucleotide inhibitor of apolipoprotein B-100
Serum apolipoprotein B-100
concentrations in healthy and diseased cattle.
VLDL is assembled on apolipoprotein B-100
(apoB100) and comprises 50% TG, 20% cholesterol esters, 15% phospholipids and 15% protein.
Lp (a) is an LDL-like particle having an apolipoprotein (a) which is attached to apolipoprotein B-100
by a disulfide linkage.
gene Xba I polymorphism and cholesterol gallstone disease.
In this paper, we first review LDL, apolipoprotein B-100
, the unique protein of LDL, and its oxidation sensitive components.